{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:10:09Z","timestamp":1792404609278,"version":"4.4.0"},"reference-count":154,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005593","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T23:08:27Z","timestamp":1137712107000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":799,"title":["Cholinesterase inhibitors for Alzheimer's disease"],"prefix":"10.1002","volume":"2016","author":[{"given":"Jacqueline S","family":"Birks","sequence":"first","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; Botnar Research Centre, Windmill Road Oxford UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Feldman H. Gauthier S. Hecker J. Vellas B. Subbiah P. Whalen E. Donepezil MSAD Study Investigators Group Erratum: a 24-week, randomized, double-blind study of donepezil in moderate to severe alzheimer's disease Neurology 2001 2153","DOI":"10.1212\/WNL.57.11.2153-a"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0003|cit3","first-page":"A100","article-title":"Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation. Presented at the annual meeting of the American Academy of Neurology. Boston","volume":"48","author":"Friedhoff","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0004|cit4","unstructured":"Friedhoff LT Rogers SL Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17, Vienna, Austria 1997 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD005593-BIB0005|cit5","first-page":"S9","article-title":"Donepezil maintains activities of daily living in patients with mild to moderately severe Alzheimer's disease: results of a retrospective analysis","volume":"4, Suppl 1","author":"Friedhoff","year":"1997","journal-title":"Eur J Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0011|cit6","unstructured":"Rogers SL Donepezil new clinical trials support long term use Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 133"},{"key":"10.1002\/14651858.CD005593-BIB0006|cit7","first-page":"A217 S14.001 AR","article-title":"E2020 produces both clinical, global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial","volume":"46","author":"Rogers","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0007|cit8","unstructured":"Rogers SL Doody R Mohs R Friedhoff T Donepezil Study Group E2020 (Aricept TM) improves global and cognitive function in patients with Alzheimer's Disease. Results of a 30-week trial unpublished paper 1996b"},{"issue":"1","key":"10.1002\/14651858.CD005593-BIB0008|cit9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0009|cit10","unstructured":"Rogers SL Friedhoff LT Farlow MR Doody RS Mohs R Efficacy of donepezil in Alzheimer's disease: Fact or artifact? [Reply] Neurology 1999 218 9"},{"key":"10.1002\/14651858.CD005593-BIB0010|cit11","unstructured":"Rogers SL Mohs RC Friedhoff LT Donepezil (E2020) improves cognition and function in patients with mild to moderately severe Alzheimer's disease. Results from Phase III trials American Psychiatric Association 150th Annual Meeting, San Diego 1997"},{"key":"10.1002\/14651858.CD005593-BIB0012|cit12","unstructured":"Bayer AJ Rossor M Hecker J Gauthier S Burns A Petite H Moller HJ Rogers SL Friedhoff LT International Donepezil Study Group Donepezil improves functional activity in patients with Alzheimer's disease Proceedings of the 21st Collegium Internationale Neuro psychopharmacologicum; 1998 Jul 12-16, Glasgow, Scotland 1998 SR-HANDSRCH"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1002\/14651858.CD005593-BIB0014|cit14","unstructured":"Gauthier S Rosser M Hecker J Petite H Rogers S Mohr E Burns A Friedhoff LT Rogers S Donepezil Produces Both Clinical Global and Cognitive Test Improvement in Patients with Alzheimer's Disease Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4, Toronto, Canada 1998b SR-HANDSRCH"},{"key":"10.1002\/14651858.CD005593-BIB0015|cit15","unstructured":"Gauthier S Rossor M Hecker J Results from a multinational Phase III clinical trial of donepezil in Alzheimer's disease [abstract] [poster presentation at 5th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy]"},{"key":"10.1002\/14651858.CD005593-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Pratt RD Gauthier S Burns A Perdomo CA Donepezil provides long-term clinical benefits for patients with Alzheimers Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000a","DOI":"10.1016\/S0197-4580(00)82652-4"},{"key":"10.1002\/14651858.CD005593-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Finucane TE Tariot PN Cummings JL Katz IR Mintzer J Perdomo CA Schwam EM Whalen E Getting donepezil into the nursing home. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting Journal of the American Geriatrics Society 2003 133 134","DOI":"10.1034\/j.1601-5215.2002.51025.x"},{"issue":"1","key":"10.1002\/14651858.CD005593-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1601-5215.2002.51022.x","article-title":"Donepezil for nursing home patients with dementia: a reinterpretation of the evidence. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting J Am Geriatr Soc 2001;49:1590-9.","volume":"51","author":"Steinman","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD005593-BIB0019|cit19","unstructured":"Tariot P Cummings JL Katz IR Perdomo CA Whalen E Sovel MA Schwam EM Donepezil was well-tolerated and enhanced cognition in nursing home patients with alzheimer's disease Journal of the American Geriatrics Society 1999 S3"},{"key":"10.1002\/14651858.CD005593-BIB0020|cit20","unstructured":"Tariot P Perdomo CA Whalen E Sovel MA Scham EM Age is not a barrier to donepezil treatment of Alzheimer's disease in the long-term care setting International Psychogeriatrics 1999 134"},{"key":"10.1002\/14651858.CD005593-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Tariot PN Cummings JL Katz IR Mintzer J Perdomo CA Schwam EM Whalen E A randomised, double-blind, placebo-controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting Journal of the American Geriatrics Society 2001 1590 9","DOI":"10.1111\/j.1532-5415.2001.49266.x"},{"key":"10.1002\/14651858.CD005593-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease","volume":"61","author":"Seltzer","year":"2004","journal-title":"Archives of Neurolology"},{"key":"10.1002\/14651858.CD005593-BIB0031|cit23","unstructured":"Feldman H Therapeutic benefits of acetylcholinesterase inhibitor therapy in the moderate to severe stage of alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 59"},{"key":"10.1002\/14651858.CD005593-BIB0023|cit24","unstructured":"Feldman H Gauthier S Hecker J Vellas B Hux M Emir B Subbiah P Mastery V Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 285"},{"key":"10.1002\/14651858.CD005593-BIB0024|cit25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden","volume":"51","author":"Feldman","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0025|cit26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1212\/01.WNL.0000134663.79663.6E","article-title":"Economic evaluation of donepezil in moderate to severe Alzheimer disease","volume":"63","author":"Feldman","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0026|cit27","unstructured":"Feldman H Gauthier S Hecker J Vellas B Ieni J Xu Y Schwam E Treatment Benefits of Donepezil in Patients with Severe Alzheimer's Disease and Their Caregivers 57th Annual Meeting of the American Academy of Neurology, Miami Beach, April 2005 2005b:P02.097 2005"},{"key":"10.1002\/14651858.CD005593-BIB0029|cit28","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil provides benefits in global function in moderate to severe Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82641-X"},{"key":"10.1002\/14651858.CD005593-BIB0030|cit29","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil's benefits on cognition, global function, activities of daily living and behavior in patients with moderate to severe alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 174"},{"key":"10.1002\/14651858.CD005593-BIB0027|cit30","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil MSAD Study Group Benefits of Donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease Neurology 2000 A469"},{"key":"10.1002\/14651858.CD005593-BIB0028|cit31","doi-asserted-by":"crossref","unstructured":"Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 2001a 613 20","DOI":"10.1212\/WNL.57.4.613"},{"key":"10.1002\/14651858.CD005593-BIB0032|cit32","unstructured":"Gauthier S Feldman H Hecker J Vellas B Emir B McGill PS Exploratory analysis of the effects af donepezil in moderate and severe Alzheimer's disease patients The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 277"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","article-title":"Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease","volume":"14","author":"Gauthier","year":"2002","journal-title":"International Psychogeriatrics"},{"issue":"6","key":"10.1002\/14651858.CD005593-BIB0034|cit34","first-page":"347","article-title":"Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease","volume":"18","author":"Gauthier","year":"2002","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD005593-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Gauthier S Feldman H Hecker J Vellas B Subbiah P Whalen E Benefits of Donepezil on performance of basic and instrumental activities of daily living in moderate to sever Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000a","DOI":"10.1016\/S0197-4580(00)82065-5"},{"key":"10.1002\/14651858.CD005593-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Gauthier S Feldman H Hecker J Vellas B Subbiah P Whalen E Effects of donepezil on behaviour and other domains in moderate to severe alzheimer's disease Journal of the European College of Neuropsychopharmacology 2000b S359 SR-HANDSRCH","DOI":"10.1016\/S0924-977X(00)80473-3"},{"key":"10.1002\/14651858.CD005593-BIB0037|cit37","unstructured":"Gauthier S Feldman H Vellas B Subbiah P Efficacy of donepezil on functional, behavioural and cognitive symptoms in patients with moderate to severe alzheimer's disease Journal of the American Geriatrics Society 2000 S2"},{"key":"10.1002\/14651858.CD005593-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Hecker J Foti D Gauthier S Vellas B Subbiah P Whalen E Benefits of Donepezil in the treatment of behavioural problems in moderate to severe Alzheimer's Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82066-7"},{"key":"10.1002\/14651858.CD005593-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Luckmann R Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease ACP-Journal-Club 2002 59","DOI":"10.7326\/ACPJC-2002-136-2-059"},{"key":"10.1002\/14651858.CD005593-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Panisset M Feldman H Gauthier S Hecker J Vellas B Subbiah P Whalen E Use of the severe impairment battery in a clinical trial of Donepezil in moderate to severe Alzheimers Disease Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82648-2"},{"issue":"S2","key":"10.1002\/14651858.CD005593-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0197-4580(04)80698-5","article-title":"Pharmacoeconomic Benefits of Donepezil Treatment in Severe Alzheimer's Disease","volume":"25","author":"Shah","year":"2004","journal-title":"NeuroBiology of Aging"},{"key":"10.1002\/14651858.CD005593-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Vellas B Feldman H Gauthier S Hecker J Subbiah P Whalen E Mastey V Donepezil treatment in patients with moderate to severe Alzheimer's Disease reduces caregiver stress Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82647-0"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005593-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1016\/S0924-977X(00)80492-7","article-title":"Donepezil improved or stabilized cognition over one year in patients with mild and moderate alzheimer's disease","volume":"10","author":"Engedal","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0044|cit44","first-page":"S131","article-title":"An economic evaluation of donepezil in mild to moderate alzheimer's disease: results of a one year, double-blind, randomized trial","volume":"49","author":"Mastey","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD005593-BIB0045|cit45","unstructured":"Mastey V Wimo A Winblad B Haglund A Jacobson L Miceli R Zhang R Subbiah P Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"key":"10.1002\/14651858.CD005593-BIB0046|cit46","unstructured":"Soininen H Winblad B Engedal K Verhey F Waldemar G Wimo A Wetterholme AL Zhang R Hugland A Subbiah P Long term benefits of donepezil on ADLs in AD patients Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville. 2000 171"},{"key":"10.1002\/14651858.CD005593-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Soininen H Winblad B Engedal K Verhey F Waldemar G Wimo A Zhang R Subbiah P Donepezil Nordic Study Group Response to Donepezil is not predicted by apolipoprotein E genotype and\/or gender Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington 2000","DOI":"10.1016\/S0197-4580(00)82062-X"},{"key":"10.1002\/14651858.CD005593-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Waldemar G Winblad B Engedal K Soininen H Donepezil Nordic Study Group et al Benefits of Donepezil on cognition, function and\/or neuropsychiatric symtoms in patients with Alzheimers Disease over one year Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)83186-3"},{"key":"10.1002\/14651858.CD005593-BIB0049|cit49","unstructured":"Waldemar G Winblad B Engedal K Soininen HS Verhey FR Wimo A Wetterholm AL Zhang R Haglund AA Subbiag P Donepezil Nordic Study Group Donepezil benefits patients with either mild of moderate Alzheimer's disease over one year Neurology 2000 A470"},{"issue":"2","key":"10.1002\/14651858.CD005593-BIB0053|cit50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000071697","article-title":"Erratum: an economic evaluation of donepezil in mild to moderate alzheimer's disease: results of a 1-year, double-blind, randomized trial (dementia and geriatric cognitive disorders (2003) 15 (44-54))","volume":"16","author":"Wimo","year":"2003","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"1","key":"10.1002\/14651858.CD005593-BIB0050|cit51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000066669","article-title":"An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial","volume":"15","author":"Wimo","year":"2003","journal-title":"Dementia and geriatric cognitive disorders"},{"key":"10.1002\/14651858.CD005593-BIB0051|cit52","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V An economic evaluation of Donepezil in mild to moderate Alzheimers Disease: Results of a one-year, double-blind, randomized trial Proceedings of the World Alzheimer Congress; 2000 Jul 9-13, Washington DC 2000","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD005593-BIB0052|cit53","doi-asserted-by":"crossref","unstructured":"Wimo A Winblad B Mastey V Haglund A Hertzman P Miceli R Jacobson L Subbiah P An economic evaluation of donepezil in mild to moderate alzheimer's disease patients: results of a one-year, double-blind, randomized trial Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH","DOI":"10.1016\/S0197-4580(00)82504-X"},{"key":"10.1002\/14651858.CD005593-BIB0057|cit54","unstructured":"Winblad B Long term therapeutic benefits of acetylcholinesterase inhibitor therapy in patients with alzheimer's disease Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm 2000 164"},{"key":"10.1002\/14651858.CD005593-BIB0054|cit55","doi-asserted-by":"crossref","unstructured":"Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Wetterholm A Zhang R Haglund A Subbiah P A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 2001 489 95","DOI":"10.1212\/WNL.57.3.489"},{"key":"10.1002\/14651858.CD005593-BIB0055|cit56","unstructured":"Winblad B Engedal K Soininen H Verhey F Waldemar G Wimo A Wetterholm AL Zhang R Haglund A Subbiah P Donepezil enhances global function and acitivities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate alzheimer's disease Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD005593-BIB0056|cit57","first-page":"138","article-title":"Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease","volume":"11","author":"Winblad","year":"1999","journal-title":"International Psychogeriatrics"},{"issue":"8","key":"10.1002\/14651858.CD005593-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Current Medical Research and Opinions"},{"issue":"7278","key":"10.1002\/14651858.CD005593-BIB0060|cit59","first-page":"90","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))","volume":"322","author":"Wilcock","year":"2001","journal-title":"BR-MED-J: British-Medical-Journal"},{"key":"10.1002\/14651858.CD005593-BIB0061|cit60","doi-asserted-by":"crossref","unstructured":"Wilcock GK GALANTAMINE ALLEVIATES CAREGIVER BURDEN IN ALZHEIMER'S DISEASE: A 6-MONTH PLACEBO-CONTROLLED STUDY Conference Proceedings World Alzheimer Congress; 9-13 July, 2000, Washington 2000","DOI":"10.1016\/S0197-4580(00)83423-5"},{"key":"10.1002\/14651858.CD005593-BIB0059|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"British Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD005593-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galamtine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005593-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0064|cit64","first-page":"S151","article-title":"Effects dof Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment","volume":"49","author":"Anand","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD005593-BIB0065|cit65","unstructured":"Anand R Messina J Veach J Hartman R Effects of Rivastigmine in patients with moderately severe Alzheimer's disease Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 199"},{"key":"10.1002\/14651858.CD005593-BIB0066|cit66","unstructured":"Farlow M Anand R Messina J Hartman R Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co-existing vascular risk Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 206"},{"key":"10.1002\/14651858.CD005593-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Farlow M Messina J Anand R Hartman R Veach J Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease In: Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden. 2000 2000 172","DOI":"10.1017\/S109285290000701X"},{"issue":"32","key":"10.1002\/14651858.CD005593-BIB0068|cit68","first-page":"1757","article-title":"[Alzheimer disease: efficacy and tolerance of rivastigmine]","volume":"28","author":"Hebert","year":"1999","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD005593-BIB0069|cit69","unstructured":"Kumar V Messina J Hartman R Anand R Long-term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000 215"},{"key":"10.1002\/14651858.CD005593-BIB0070|cit70","unstructured":"Lindesay J An open label one-year extension of SDZ-ENA-713 studies B303, B304 and B305 to prospectively evaluate long-term safety, tolerability and efficacy of SDZ-ENA-713 in out-patients with probable Alzheimer's disease National Research Register 2000"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0075|cit71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1155\/1999\/168023","article-title":"Effect of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease","volume":"11","author":"Roesler","year":"1998","journal-title":"Behavioural-Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0074|cit72","unstructured":"R\u00f6sler M Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum] British Medical Journal 2001 1456"},{"issue":"7184","key":"10.1002\/14651858.CD005593-BIB0071|cit73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005593-BIB0072|cit74","first-page":"212","article-title":"A double-blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT)","volume":"30","author":"R\u00f6sler","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0073|cit75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1155\/1999\/168023","article-title":"Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease","volume":"11","author":"R\u00f6sler","year":"1998","journal-title":"Behavioural-Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0076|cit76","unstructured":"Vincent S Andrews C Lane R Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 253"},{"issue":"2","key":"10.1002\/14651858.CD005593-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7326\/ACPJC-1999-131-2-034","article-title":"Rivastigmine was effective and safe in Alzheimer disease","volume":"131","author":"Wilkinson","year":"1999","journal-title":"ACP Journal Club"},{"key":"10.1002\/14651858.CD005593-BIB0078|cit78","unstructured":"Lindesay J An open label one-year extension of SDZ-ENA-713 studies B303, B304 and B305 to prospectively evaluate long-term safety, tolerability and efficacy of SDZ-ENA-713 in out-patients with probable Alzheimer's disease National Research Register 2000"},{"key":"10.1002\/14651858.CD005593-BIB0080|cit79","unstructured":"Novartis No title Unpublished. Data provided by Novartis"},{"key":"10.1002\/14651858.CD005593-BIB0079|cit80","unstructured":"Novartis Pharmaceuticals ADENA Programme Unpublished Data 1998"},{"key":"10.1002\/14651858.CD005593-BIB0082|cit81","unstructured":"Novartis No title Unpublished. Data provided by Novartis"},{"key":"10.1002\/14651858.CD005593-BIB0081|cit82","unstructured":"Novartis Pharmaceuticals ADENA Programme Unpublished Data 1998"},{"key":"10.1002\/14651858.CD005593-BIB0083|cit83","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease","volume":"1","author":"Corey-Bloom","year":"1998","journal-title":"Int J Ger Psychopharmacology"},{"key":"10.1002\/14651858.CD005593-BIB0084|cit84","unstructured":"Doraiswamy M The effects of rivastigmine on the alzheimer's disease assessment scale-cognitive subscale items scores of patients with alzheimer's disease Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American geriatrics society and the American federation for aging research; 2000 May 17-21, Nashville 2000 173"},{"issue":"6","key":"10.1002\/14651858.CD005593-BIB0085|cit85","first-page":"12","article-title":"Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately-severe to severe AD","volume":"1","author":"Doraiswamy","year":"2000","journal-title":"Clinical Neuropschological Assessment"},{"issue":"6","key":"10.1002\/14651858.CD005593-BIB0086|cit86","first-page":"14","article-title":"Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine","volume":"1","author":"Doraiswamy","year":"2000","journal-title":"Clinical Neuropschological Assessment"},{"key":"10.1002\/14651858.CD005593-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Farlow M Hake A Messina J Veach J Anand R The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression Neurology 2000 A469","DOI":"10.1001\/archneur.58.3.417"},{"key":"10.1002\/14651858.CD005593-BIB0088|cit88","unstructured":"Farlow M Messina J Anand R Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17-21, Nashville 2000 172"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archneur.58.3.417","article-title":"Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression","volume":"58","author":"Farlow","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0090|cit90","unstructured":"Ferris S Improving day to day functioning in patients with AD Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15-20, Vancouver 1999 77"},{"key":"10.1002\/14651858.CD005593-BIB0091|cit91","first-page":"S3","article-title":"Rivastigmine slows stage specific global deterioration in Alzheimer's disease","volume":"47","author":"Krishnan","year":"1999","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"10.1002\/14651858.CD005593-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors","volume":"7","author":"Kumar","year":"2000","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0093|cit93","unstructured":"Veach KR Doraiswamy PM Rivastigmine slows stage-specific global deterioration in Alzheimer's disease Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20, Washington DC 1999 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD005593-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"AD2000 Collaborative Group","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005593-BIB0095|cit95","unstructured":"Bentham P Gray R Hill R Sellwood E Courtney C Twelve week respone to cholinesterase inhibitors dose not predict future benefit the AD2000 trial experiance The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 337"},{"key":"10.1002\/14651858.CD005593-BIB0096|cit96","unstructured":"Lendon CL Determination of respones to anticholinesterase therapy in the treatment of Alzheimer's disaese The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 1287"},{"key":"10.1002\/14651858.CD005593-BIB0097|cit97","unstructured":"Lendon CL Determination of responses to anticholinesterase therapy in the treatment of Alzheimer's disease Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden: Abstract No 1287 2002"},{"key":"10.1002\/14651858.CD005593-BIB0098|cit98","unstructured":"Roberts N A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease (AD2000) National Research Register 2001"},{"key":"10.1002\/14651858.CD005593-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Schneider LS AD2000: donepezil in Alzheimer's disease Lancet 2004 2100 1","DOI":"10.1016\/S0140-6736(04)16533-1"},{"key":"10.1002\/14651858.CD005593-BIB0100|cit100","unstructured":"Waghray S AD2000 A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's disease National Research Register 2000 http:\/\/www.doh.gov.uk\/nrr.htm"},{"key":"10.1002\/14651858.CD005593-BIB0101|cit101","unstructured":"Tune L Tiseo P Hoffman J Perdomo C Votaw J Rogers S Friedhoff L PET in AD: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer's disease: results of a 24-week study Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26 San Francisco 2001"},{"issue":"2","key":"10.1002\/14651858.CD005593-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00019442-200303000-00007","article-title":"Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study","volume":"11","author":"Tune","year":"2003","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD005593-BIB0103|cit103","unstructured":"Tune LE Tiseo PJ Hoffman JM Perdomo CA Votow JR Rogers SL Friedhoff LT Functional Brain Activity in Alzheimer's Disease Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30- Jun 4, Toronto 1998 NR345 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD005593-BIB0104|cit104","unstructured":"Anon No title Eisai Inc."},{"key":"10.1002\/14651858.CD005593-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gps.1038","article-title":"A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease","volume":"19","author":"Jones","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD005593-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","article-title":"A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease","volume":"20","author":"Wilcock","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1002\/14651858.CD005593-BIB0108|cit107","unstructured":"Bullock R Passmore F Potocnik F Hock C The tolerability, ease of use and efficacy of donepezil and rivastigmine in alzeimer's disease patients: a 12-week, multinational, comparative study Journal of the American Geriatrics Society 2001 S19"},{"key":"10.1002\/14651858.CD005593-BIB0109|cit108","unstructured":"Bullock R Wilkinson DG Passmore P Hopker SW Smith R Potocnik FC Maud CM Hock C Caregiver and physician determination of satisfaction with and ease of use of donepezil and rivastigamine treatment in alzheimer's disease patients Proceedings of the 17th Alzheimer's Disease International Conference; 2001 Oct 25-27, Christchurch, New Zealand 2001 39"},{"key":"10.1002\/14651858.CD005593-BIB0107|cit109","unstructured":"B\u00f6ttcher-Buhler E [Well tolerated, effective and inexpensive therapy of Alzheimer's dementia with donepezil] Neurologie und Rehabilitation 2000 332 3"},{"key":"10.1002\/14651858.CD005593-BIB0110|cit110","unstructured":"Potocnik FC Smith R Passmore P Hock C Wilkinson D Maud CM Hopker S Tolerability, ease of use, and efficacy of donepezil and rivastigmine in alzheimer's disease patients Proceedings of the Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans 2001"},{"key":"10.1002\/14651858.CD005593-BIB0111|cit111","unstructured":"Wilkinson D Passmore P Potocnik F Maud C Hock C Donepezil compared to rivastigmine in Alzheimer's disease: similar efficacy but better tolerability and physician and caregiver satisfaction in a multinational randomized trial Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"issue":"6","key":"10.1002\/14651858.CD005593-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1742-1241.2002.tb11294.x","article-title":"A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease","volume":"56","author":"Wilkinson","year":"2002","journal-title":"International Journal of Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005593-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-4943(01)00134-0","article-title":"Cognitive deficits in alzheimer's disease: treatment with acetylcholinesterase inhibitor agents","volume":"33","author":"Fuschillo","year":"2001","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"2-3","key":"10.1002\/14651858.CD005593-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer's Disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1002\/14651858.CD005593-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005593-BIB0116|cit116","unstructured":"Erkinjuntti T Kurz A Gauthier S Bullock R Lilienfeld S Damaraju CV The safety and efficacy of Galantamine in the treatment of vascular and mixed dementia (Double-blind part only). (GAL-INT-6) Johnson and Johnson Pharmaceutical Research & Development. January 2004"},{"issue":"11","key":"10.1002\/14651858.CD005593-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"American journal of psychiatry, The"},{"key":"10.1002\/14651858.CD005593-BIB0118|cit118","unstructured":"Mega M Dinov I Manese M Felix J O'Connor S Toga A Cummings J Cerebral metabolic activation with cholinesterase inhibitor therapy in Alzheimer's disease The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 430"},{"key":"10.1002\/14651858.CD005593-BIB0119|cit119","unstructured":"Rozzini L Bargnani C Bosio A Chia F Franzani S Leonardi R Ranzenigo A Rozzini R Saviotti FM Turla M Trabucchi m Ghianda D Borroni B Chilovi BV Padovani A Acetylcholinesterase inhibitors are effective in real world patients with mild to moderate Alzheimer disease evidence from a large population treated with rivastigmine or donepezil The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 329"},{"key":"10.1002\/14651858.CD005593-BIB0120|cit120","unstructured":"Rozzini L Bargnani C Bosio A Chia F Franzoni S Leonardi R Ranzenigo A Rozzini R Saviotti FM Turla M Trabucchi M Vicini B Borroni B Padovani A Comparison of efficacy and safety of rivastigmine and donepezil in patients with mild to moderate alzheimer disease: results from a multicentre randomised trial. The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 240"},{"key":"10.1002\/14651858.CD005593-BIB0121|cit121","unstructured":"Shua-Haim J Smith J Potel S A head to study of donepezitl aricept rivastigmine exlon and galantamine reminyl for the treatment of Alzheimer's disease safety tolerability clinical and caregiver impression after 4-5 months of trratment a prospective study The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 286"},{"key":"10.1002\/14651858.CD005593-BIB0122|cit122","unstructured":"Ebell M Does donepezil help patients with moderate Alzheimer's dementia preserve their ability to function independently? Evidence Based Practice 2002"},{"key":"10.1002\/14651858.CD005593-BIB0123|cit123","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni J Perdomo C Pratt R Rogers S Donepezil preserves activities of daily living in alzheimer's disease patients: results from a one-year placebo-controlled functional survival study Neurology 2000 A415","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD005593-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni J Rogers S Perdomo C Pratt R Donepezil preserves functional status and improves cognition in alzheimer's disease patients: results from a 1-year propective placebo-controlled study Journal of the American Geriatrics Society 2000 S46","DOI":"10.1016\/S0924-977X(99)80460-X"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005593-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(99)80460-X","article-title":"Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study","volume":"9","author":"Mohs","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005593-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Mohs R Doody R Morris J Ieni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study Proceedings of the Quality Research in Dementia Conference; 2000 Nov 19-22, London 2000","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD005593-BIB0127|cit127","doi-asserted-by":"crossref","unstructured":"Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo C Pratt RD 312 Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [Erratum] Neurology 2001 1942 http:\/\/www.lww.com","DOI":"10.1212\/WNL.57.10.1942-a"},{"key":"10.1002\/14651858.CD005593-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Mohs RC Doody RS Morris JC Ieni JR Rogers SL Perdomo CA Pratt RD A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 2001 481 8","DOI":"10.1212\/WNL.57.3.481"},{"key":"10.1002\/14651858.CD005593-BIB0129|cit129","unstructured":"Mohs RC Doody RS Morris JC Leni JR Rogers SL Perdomo CA Pratt RD Donepezil preserves functional status in Alzheimer's disease Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18, Chicago, Illionois 2000 SR-HANDSRCH"},{"key":"10.1002\/14651858.CD005593-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Pratt R Mohs R Doody R Morris J Rogers S Ieni J Perdomo C Donepezil preserves functional status in Alzheimer's disease patients results from a 1-year prospective placebo controlled functional study Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; April 5-8, 2000; Stockholm, Sweden 2000b 178","DOI":"10.1016\/S0924-977X(99)80460-X"},{"key":"10.1002\/14651858.CD005593-BIB0131|cit131","unstructured":"Tsolaki M Gerothanassis D Aristotle CP Efficacy and safety of cholinesterase inhibitors a longitudinal comparative study between donepezil and rivastigmine The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 2038"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0132|cit132","first-page":"210","article-title":"The treatment by using rivastigmine for patients with alzheimer disease: results of a multicenter, randomized, open-labeled, controlled clinical trial","volume":"34","author":"Wang","year":"2001","journal-title":"Chinese Journal of Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0133|cit133","unstructured":"Werber EA Klein C Rabey MJ Evaluation of cholinergic treatment in demented by p300 evoked related potentials The 8th conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002 442"},{"key":"10.1002\/14651858.CD005593-BIB0134|cit134","first-page":"American Psychi","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0135|cit135","article-title":"Donepezil for dementia due to Alzheimer's disease (Cochrane Review)","author":"Birks","year":"2005","journal-title":"The Cochrane Library"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0136|cit136","article-title":"Rivastigmine for Alzheimer's disease (Cochrane Review)","author":"Birks","year":"2005","journal-title":"The Cochrane Library"},{"key":"10.1002\/14651858.CD005593-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ageing\/25.2.113","article-title":"Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale","volume":"25","author":"Bucks","year":"1996","journal-title":"Age Ageing"},{"key":"10.1002\/14651858.CD005593-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005593-BIB0139|cit139","first-page":"545","article-title":"Measurement of quality-of-life changes in patients with Alzheimer's disease","volume":"11","author":"DeJong","year":"1989","journal-title":"Clin Ther"},{"issue":"10","key":"10.1002\/14651858.CD005593-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1742-1241.2002.tb11377.x","article-title":"Rivastigmine in patients with Alzheimer's disease and concurrent hypertension","volume":"56","author":"Erkinjuntti","year":"2002","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD005593-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005593-BIB0142|cit142","first-page":"533","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1002\/14651858.CD005593-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1002\/14651858.CD005593-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"American Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD005593-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD005593-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors","volume":"7","author":"Kumar","year":"2000","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0147|cit147","article-title":"Galantamine for Alzheimer's disease (Cochrane Review)","author":"Loy","year":"2005","journal-title":"The Cochrane Library"},{"key":"10.1002\/14651858.CD005593-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer\u2019s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005593-BIB0149|cit149","article-title":"Galantamine for Alzheimer's disease (Cochrane Library)","author":"Olin","year":"2005","journal-title":"The Cochrane Library"},{"key":"10.1002\/14651858.CD005593-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","article-title":"Severe impairment battery. A neurological test for severely demented patients","volume":"51","author":"Panisset","year":"1994","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD005593-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"the global deterioration sclae for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD005593-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"suppl 2","key":"10.1002\/14651858.CD005593-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change","volume":"11","author":"Schneider","year":"1997","journal-title":"AD Assoc Dis"},{"key":"10.1002\/14651858.CD005593-BIB0154|cit154","first-page":"465","article-title":"Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials","volume-title":"Health Economics in Dementia","author":"Wimo","year":"1998"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005593\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T02:57:44Z","timestamp":1716260264000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005593"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":154,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005593","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,25]]}}}